Cumberland Pharmaceuticals Inc (CPIX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Cumberland Pharmaceuticals Inc stock (CPIX) is currently trading at $3.13. Cumberland Pharmaceuticals Inc PS ratio (Price-to-Sales) is 0.95. Analyst consensus price target for CPIX is $8.50. WallStSmart rates CPIX as Underperform.
- CPIX PE ratio analysis and historical PE chart
- CPIX PS ratio (Price-to-Sales) history and trend
- CPIX intrinsic value — DCF, Graham Number, EPV models
- CPIX stock price prediction 2025 2026 2027 2028 2029 2030
- CPIX fair value vs current price
- CPIX insider transactions and insider buying
- Is CPIX undervalued or overvalued?
- Cumberland Pharmaceuticals Inc financial analysis — revenue, earnings, cash flow
- CPIX Piotroski F-Score and Altman Z-Score
- CPIX analyst price target and Smart Rating
Cumberland Pharmaceuticals Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Cumberland Pharmaceuticals Inc (CPIX) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book, revenue growth. Concerns around market cap and return on equity. Mixed signals suggest waiting for clearer direction before acting.
Cumberland Pharmaceuticals Inc (CPIX) Key Strengths (3)
Paying less than $1 for every $1 of annual revenue
Revenue surging 31.10% year-over-year
Trading at 1.70x book value, attractively priced
Supporting Valuation Data
Cumberland Pharmaceuticals Inc (CPIX) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Micro-cap company with very limited liquidity and high volatility
Low institutional interest, mostly retail-driven
Growth is fairly priced, not cheap, not expensive
Supporting Valuation Data
Cumberland Pharmaceuticals Inc (CPIX) Detailed Analysis Report
Overall Assessment
This company scores 44/100 in our Smart Analysis, earning a D grade. Out of 9 metrics analyzed, 3 register as strengths (avg 9.3/10) while 6 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Revenue Growth, Price/Book. Valuation metrics including Price/Sales (0.95), Price/Book (1.70) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 31.10%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including PEG Ratio (1.67) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -12.20%, Operating Margin at -10.00%, Profit Margin at -6.37%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -12.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 31.10% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CPIX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CPIX's Price-to-Sales ratio of 0.95x trades 49% below its historical average of 1.88x (16th percentile). The current valuation is 87% below its historical high of 7.14x set in Aug 2009, and 107% above its historical low of 0.46x in Oct 2024. Over the past 12 months, the PS ratio has compressed from ~1.7x as trailing revenue scaled faster than the stock price.
Compare CPIX with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Cumberland Pharmaceuticals Inc (CPIX) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Cumberland Pharmaceuticals Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 45M with 31% growth year-over-year. The company is currently unprofitable, posting a -6.4% profit margin.
Key Findings
Revenue growing at 31% YoY, reaching 45M. This pace significantly outperforms most DRUG MANUFACTURERS - SPECIALTY & GENERIC peers.
Generating 3,018 in free cash flow and 3,024 in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -6.4% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Growth sustainability: can Cumberland Pharmaceuticals Inc maintain 31%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Cumberland Pharmaceuticals Inc.
Bottom Line
Cumberland Pharmaceuticals Inc is a high-conviction growth story with revenue accelerating at 31% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -6.4% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Cumberland Pharmaceuticals Inc(CPIX)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and marketing of prescription products for hospital acute care, gastroenterology, and rheumatology in the United States and internationally. The company is headquartered in Nashville, Tennessee.